HUTCHMED (China) Limited presented pivotal Phase II data for fanregratinib in intrahepatic cholangiocarcinoma at the ESMO Gastrointestinal Cancers Congress 2026. The filing includes a press release detailing these clinical results. The company operates in the biopharmaceutical industry, focusing on the discovery and development of innovative medicines.
